Commonwealth Equity Services’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $964K | Sell |
4,251
-819
| -16% | -$146K | ﹤0.01% | 2739 |
|
|
2026
Q1 | $875K | Sell |
5,070
-4,279
| -46% | -$793K | ﹤0.01% | 2721 |
|
|
2025
Q4 | $1.86M | Sell |
9,349
-770
| -8% | -$140K | ﹤0.01% | 2042 |
|
|
2025
Q3 | $1.58M | Buy |
10,119
+305
| +3% | +$48.4K | ﹤0.01% | 2208 |
|
|
2025
Q2 | $1.49M | Sell |
9,814
-927
| -9% | -$124K | ﹤0.01% | 2247 |
|
|
2025
Q1 | $1.62M | Sell |
10,741
-1,112
| -9% | -$186K | ﹤0.01% | 2079 |
|
|
2024
Q4 | $2.19M | Sell |
11,853
-1,932
| -14% | -$372K | ﹤0.01% | 1802 |
|
|
2024
Q3 | $2.71M | Sell |
13,785
-6,150
| -31% | -$1.28M | ﹤0.01% | 1609 |
|
|
2024
Q2 | $4.12M | Sell |
19,935
-1,554
| -7% | -$352K | 0.01% | 1304 |
|
|
2024
Q1 | $5.82M | Buy |
21,489
+453
| +2% | +$108K | 0.01% | 1080 |
|
|
2023
Q4 | $4.97M | Sell |
21,036
-9,684
| -32% | -$1.9M | 0.01% | 1102 |
|
|
2023
Q3 | $6.02M | Buy |
30,720
+2,643
| +9% | +$543K | 0.01% | 933 |
|
|
2023
Q2 | $5.9M | Buy |
28,077
+4,629
| +20% | +$921K | 0.01% | 943 |
|
|
2023
Q1 | $4.73K | Buy |
23,448
+3,811
| +19% | +$864K | 0.01% | 1024 |
|
|
2022
Q4 | $4.28M | Buy |
19,637
+220
| +1% | +$48K | 0.01% | 1046 |
|
|
2022
Q3 | $3.82M | Buy |
19,417
+1,958
| +11% | +$423K | 0.01% | 1035 |
|
|
2022
Q2 | $3.73M | Buy |
17,459
+890
| +5% | +$217K | 0.01% | 1051 |
|
|
2022
Q1 | $4.71M | Sell |
16,569
-2,183
| -12% | -$673K | 0.01% | 972 |
|
|
2021
Q4 | $7.07M | Buy |
18,752
+2,216
| +13% | +$861K | 0.02% | 756 |
|
|
2021
Q3 | $6.82M | Sell |
16,536
-608
| -4% | -$253K | 0.02% | 709 |
|
|
2021
Q2 | $6.34M | Sell |
17,144
-2,294
| -12% | -$766K | 0.02% | 735 |
|
|
2021
Q1 | $5.63M | Sell |
19,438
-2,522
| -11% | -$701K | 0.02% | 727 |
|
|
2020
Q4 | $5.49M | Sell |
21,960
-26
| -0.1% | -$6.19K | 0.02% | 688 |
|
|
2020
Q3 | $4.98M | Sell |
21,986
-4,521
| -17% | -$938K | 0.02% | 645 |
|
|
2020
Q2 | $4.62M | Sell |
26,507
-289
| -1% | -$46.1K | 0.02% | 636 |
|
|
2020
Q1 | $3.38M | Buy |
26,796
+1,722
| +7% | +$258K | 0.02% | 672 |
|
|
2019
Q4 | $3.83M | Buy |
25,074
+66
| +0.3% | +$9.14K | 0.01% | 710 |
|
|
2019
Q3 | $3.31M | Sell |
25,008
-283
| -1% | -$37.9K | 0.01% | 727 |
|
|
2019
Q2 | $3.59M | Buy |
25,291
+2,326
| +10% | +$315K | 0.02% | 689 |
|
|
2019
Q1 | $3.33M | Buy |
22,965
+549
| +2% | +$72.1K | 0.02% | 695 |
|
|
2018
Q4 | $2.54M | Buy |
22,416
+300
| +1% | +$37.6K | 0.01% | 738 |
|
|
2018
Q3 | $2.98M | Sell |
22,116
-51
| -0.2% | -$6.29K | 0.01% | 745 |
|
|
2018
Q2 | $2.49M | Buy |
22,167
+390
| +2% | +$42.2K | 0.01% | 785 |
|
|
2018
Q1 | $2.32M | Sell |
21,777
-1,211
| -5% | -$131K | 0.01% | 786 |
|
|
2017
Q4 | $2.52M | Buy |
22,988
+312
| +1% | +$34K | 0.01% | 738 |
|
|
2017
Q3 | $2.45M | Sell |
22,676
-201
| -0.9% | -$20.6K | 0.01% | 711 |
|
|
2017
Q2 | $2.31M | Buy |
22,877
+5,252
| +30% | +$483K | 0.01% | 708 |
|
|
2017
Q1 | $1.58M | Sell |
17,625
-62
| -0.4% | -$5.27K | 0.01% | 868 |
|
|
2016
Q4 | $1.35M | Sell |
17,687
-100
| -0.6% | -$7.59K | 0.01% | 899 |
|
|
2016
Q3 | $1.48M | Sell |
17,787
-42
| -0.2% | -$3.52K | 0.01% | 815 |
|
|
2016
Q2 | $1.47M | Sell |
17,829
-100
| -0.6% | -$8.24K | 0.01% | 792 |
|
|
2016
Q1 | $1.36M | Sell |
17,929
-1
| -0% | -$74 | 0.01% | 810 |
|
|
2015
Q4 | $1.44M | Buy |
17,930
+6
| +0% | +$433 | 0.01% | 744 |
|
|
2015
Q3 | $1.14M | Buy |
17,924
+125
| +0.7% | +$8.98K | 0.01% | 837 |
|
|
2015
Q2 | $1.25M | Buy |
+17,799
| New | +$1.32M | 0.01% | 845 |
|
Other funds holding CRL
CB
BTW
CIM
RP
JPMIA
Commonwealth Equity Services's CRL Position: Q2 2026 in Review
Commonwealth Equity Services reduced its Charles River Laboratories (CRL) stake by 16% in Q2 2026, selling an estimated $146K and leaving 4,251 shares worth $964K. The position accounts for ﹤0.01% of the portfolio, ranked #2739.
Commonwealth Equity Services first reported a position in CRL in Q2 2015 and has held it in 45 quarters since. The position peaked at $7.07M in Q4 2021. 173 funds tracked by Wall St. Rank hold CRL as of Q2 2026.
- Commonwealth Equity Services held 4,251 shares of Charles River Laboratories worth $964K as of Q2 2026.
- Commonwealth Equity Services sold 819 Charles River Laboratories shares in Q2 2026, an estimated $146K.
- Charles River Laboratories made up ﹤0.01% of Commonwealth Equity Services's portfolio in Q2 2026, its #2739 holding.
- Commonwealth Equity Services first reported a position in Charles River Laboratories in Q2 2015 and has held it in 45 quarters since.
- Commonwealth Equity Services's Charles River Laboratories position peaked at $7.07M in Q4 2021.
- 173 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.
Based on Commonwealth Equity Services's 13F filing for Q2 2026, filed 29 Jul 2026.